Literature DB >> 16933360

Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus.

Louise A Veltrop-Duits1, Bianca Heemskerk, Claudia C Sombroek, Tamara van Vreeswijk, Sophie Gubbels, René E M Toes, Cornelis J M Melief, Kees L M C Franken, Menzo Havenga, Maarten J D van Tol, Marco W Schilham.   

Abstract

The immune response against human adenovirus (HAdV) has gained interest because of the application of HAdV-based vectors in gene therapy and the high incidence of infections in pediatric recipients of allogeneic stem cell grafts. Because antiviral medication is frequently ineffective, the option of adoptive transfer of HAdV-specific donor-derived T cells in these immunocompromised patients is investigated. To generate good manufacturing practice-compatible reagents, a panel of 63 long, overlapping, peptides of the hexon protein was screened for recognition by T cells. Five conserved peptides of 30 amino acids were identified that were recognized by the majority of adult donors. CD4+ T cells from long-term cultures of PBMC, stimulated with this set of five peptides, recognized cells infected with HAdV serotypes belonging to different species. These data demonstrate that adult human T cells preferentially recognize conserved sequences of amino acid residues from a structural protein of HAdV. In the context of gene therapy, this observation may limit the beneficial effect of switching to HAdV-based vectors derived from less common serotypes of HAdV in an attempt to circumvent pre-existing immunity. However, this cross-reactivity benefits the application of HAdV-specific T cells for adoptive immunotherapy in immunocompromised transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16933360     DOI: 10.1002/eji.200535786

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.

Authors:  Dongming Zhou; Te-Lang Wu; Kristel L Emmer; Raj Kurupati; Steven Tuyishime; Yan Li; Wynetta Giles-Davis; Xiangyang Zhou; Zhiquan Xiang; Qin Liu; Sarah J Ratcliffe; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

3.  Mesenchymal stromal cell therapy is associated with increased adenovirus-associated but not cytomegalovirus-associated mortality in children with severe acute graft-versus-host disease.

Authors:  Friso G J Calkoen; Carly Vervat; Astrid G S van Halteren; Marij J P Welters; Louise A Veltrop-Duits; Arjan C Lankester; R Maarten Egeler; Lynne M Ball; Maarten J D van Tol
Journal:  Stem Cells Transl Med       Date:  2014-06-05       Impact factor: 6.940

4.  Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive.

Authors:  Natalie A Hutnick; Diane Carnathan; Korey Demers; George Makedonas; Hildegund C J Ertl; Michael R Betts
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 5.  How I treat adenovirus in hematopoietic stem cell transplant recipients.

Authors:  Caroline A Lindemans; Ann M Leen; Jaap Jan Boelens
Journal:  Blood       Date:  2010-09-13       Impact factor: 22.113

6.  Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.

Authors:  Maarten L Zandvliet; J H Frederik Falkenburg; Ellis van Liempt; Louise A Veltrop-Duits; Arjan C Lankester; Jayant S Kalpoe; Michel G D Kester; Dirk M van der Steen; Maarten J van Tol; Roel Willemze; Henk-Jan Guchelaar; Marco W Schilham; Pauline Meij
Journal:  Haematologica       Date:  2010-06-18       Impact factor: 9.941

Review 7.  Adenovirus DNA replication.

Authors:  Rob C Hoeben; Taco G Uil
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

Review 8.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

Review 9.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

10.  Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Authors:  Ann M Leen; Anne Christin; Mariam Khalil; Heidi Weiss; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.